Vaccine

Article	Citations
Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003–2024)	213
Editorial Board/Aims and Scope	201
Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS coloni	172
Editorial Board/Aims and Scope	151
Managing multiplicity in clinical vaccine studies – A case study using a gatekeeping testing strategy	148
Editorial Board/Aims and Scope	132
Tackling the burden of mumps in the military: A report of the Defense Health Board	130
Humoral and cellular immune responses induced by serogroup W135 meningococcal conjugate and polysaccharide vaccines	115
TAK − 021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice	114
Issues with infectious disease vaccine introduction into routine vaccination in Japan, and considerations for accelerating the process	106
Pediatric otitis media in Japan: A nationwide longitudinal study of the pre- and post-pneumococcal conjugate vaccine eras born in 2001 and 2010	102
COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants	95
A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years an	95
Characteristics of reported mumps cases in the United States: 2018–2023	91
Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study	91
Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination	91
“Every interaction you have …should be an opportunity to discuss and offer influenza vaccination”. Health service perspectives on influenza vaccination promotion and delivery to Aboriginal families li	90
Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys	88
Editorial Board/Aims and Scope	81
Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants	80
Erratum to “Motivational interviewing and vaccine acceptance in children: The MOTIVE study” [Vaccine 40(12) (2022) 1846–1854]	79
Corrigendum to ‘Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice’ [Vaccine 39 (2021) 6213–6220]	79
Erratum to “Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals” [Vaccine 41(37) (2023) 5469-5476]	78
Corrigendum to “Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis” [Vaccine 40(41) (2022) 5971	76
Cost-effectiveness of anti-viral treatment for infants with RSV disease in the United Kingdom	75

Evaluation of dynamics of immune responses and protective efficacy in piglets immunized with an inactivated porcine reproductive and respiratory syndrome vaccine candidate	74
Humoral immune response profile of a cattle herd vaccinated with 5- and 10-times Bakirköy strain sheep pox vaccine under field conditions	74
Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season	73
Effectiveness of the varicella vaccine in the real world, a matched case-control study	71
Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study	70
Pneumonia hospitalization after introduction of pneumococcal conjugate vaccine in Japan: Descriptive study using a nationwide claims database	70
Long-term impact of rotavirus vaccination on all-cause and rotavirus-specific gastroenteritis and strain distribution in Central Kenya: An 11-year interrupted time-series analysis	69
The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana	68
UK healthcare professionals’ attitudes towards the introduction of varicella vaccine into the routine childhood vaccination schedule and their preferences for administration	68
Compliance, procrastination and refusal: American COVID-19 vaccination trust and value orientation	68
Stability studies for the identification of critical process parameters for a pharmaceutical production of the Orf virus	68
Evaluating concurrency and gaps between self-report and vaccine card data for COVID-19 vaccination	67
Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea	66
Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations	65
Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England	63
Vaccination during febrile illness, what do we know? A systematic-narrative hybrid review of the literature and international recommendations	62
A universal live vaccine platform against multiple serotypes Streptococcus suis based on polyvalent antigen protein	59
Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines	59
Letter to the editor: SARS-CoV-2 vaccination in children and adolescents with neurodevelopmental or psychiatric disorders	59
Vaccination coverage in hematological patients undergoing chemotherapy: Should we move towards personalized vaccination?	58
Supply, then demand? Health expenditure, political leanings, cost obstacles to care, and vaccine hesitancy predict state-level COVID-19 vaccination rates	58
Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (SynflorixTM and Prevenar13TM)) on nasopharyngeal carriage and serotype-specific immune response in the fi	57
Adjuvant-dependent impacts on vaccine-induced humoral responses and protection in preclinical models of nasal and genital colonization by pathogenic Neisseria	57
Retesting the hypothesis that early Diphtheria-Tetanus-Pertussis vaccination increases female mortality: An observational study within a randomised trial	56
Vaccine financing in the Middle East and Africa: An overview from 2010 to 2019	55
Nationwide rollout of HPV vaccination in Nepal: Early key insights	55
Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis	54
The impact of Facebook’s vaccine misinformation policy on user endorsements of vaccine content: An interrupted time series analysis	53
Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental chal	53
The methodological quality of economic evaluations of measles outbreaks: A systematic review of cost-of-illness studies	52
COVID-19 and seasonal flu vaccination hesitancy: Links to personality and general intelligence in a large, UK cohort	51
Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2	51
Behaviors, perceptions, and impact of the COVID-19 pandemic and vaccination on oncology patients in New Mexico with substantial representation of racial minorities and rural residents	50
Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States	50
Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like particles co-expressing M2e5x or N2	50
An observational, cohort, multi-centre, open label phase IV extension study comparing preschool DTAP-IPV booster vaccine responses in children whose mothers were randomised to one of two pertussis-con	49
Integrating the person-centered approach with the study of vaccine hesitancy: Applying latent profile analysis to identify vaccine hesitancy subpopulations and assess their relations with correlates a	48
A decade of rotavirus vaccination in the World Health Organization African Region: An in-depth analysis of vaccine coverage from 2012 to 2023	48
The U.S. COVID-19 vaccination program: A look back and future directions	48
Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation	48
“Fighting the pandemic!” Western Australian pharmacists’ perspectives on COVID-19 vaccines: A qualitative study	48
Collateral damage from debunking mRNA vaccine misinformation	48
Purification of recombinant vesicular stomatitis virus-based HIV vaccine candidate	48
BCG for the prevention and treatment of allergic asthma	47
Epidemiological characteristics and serotype distribution of culture-confirmed pediatric pneumococcal pneumonia before and after PCV 10 introduction, a multicenter study in Bogota, Colombia, 2008–2019	46
U.S. public support and opposition to vaccination mandates in K-12 education in light of the COVID-19 pandemic	46
Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink	45
Healthcare professional and professional stakeholders’ perspectives on vaccine mandates in Switzerland: A mixed-methods study	45
World Health Organization Expert Working Group: Recommendations for assessing morbidity associated with enteric pathogens	45
Corrigendum to “Recombinant BCGΔBCG1419c protects outbred mice against M. tuberculosis challenge” [Vaccine 61 (2025) 127347]	44

Identification of T-cell epitopes of the intracellular parasite Babesia bovis by immunopeptidomic analysis of BoLA-II presented peptides	44
Genetic markers of enhanced functional antibody responses to COVID-19 vaccination	44
Use of an adapted participatory learning and action cycle to increase knowledge and uptake of child vaccination in internally displaced persons camps (IVACS): A cluster-randomised controlled trial	44
Assessing commutability of the first WHO International Standard for antiserum to respiratory syncytial virus	44
Timeliness and completeness of serial routine vaccinations among 8062 rural children in southwest China during the COVID-19 pandemic: A multi-stage stratified cluster sampling survey in 1094 villages	44
Why did Brazil fail to vaccinate children against COVID-19 during the pandemic? An assessment of attitudinal and behavioral determinants	43
Cost of illness due to pertussis in adults ≥50 years of age in the United Kingdom	43
Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study	43
Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up	43
Determinants of immunization in polio super high-risk union councils of Pakistan	43
Immunogenicity and protective efficacy of a trimeric full-length S protein subunit vaccine for porcine epidemic diarrhea virus	42
Mass vaccination campaign during the 2016 influenza outbreak in Panama: Challenges and implications for COVID-19 vaccination efforts	42
Corrigendum to ‘A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older’ Vac	42
Increasing Ebola transmission behaviors 6 months post-vaccination: Comparing vaccinated and unvaccinated populations near 2018 Mbandaka Ebola outbreak in the Democratic Republic of Congo	42
Safety surveillance of varicella vaccine using tree-temporal scan analysis	42
Safety, efficacy, and DIVA feasibility on a novel live attenuated classical swine fever marker vaccine candidate	41
Uptake of COVID-19 vaccines among healthcare workers and the effect of nudging interventions: A mixed methods study	41
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine	41
A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults	40
A place for neutrophils in the beneficial pathogen-agnostic effects of the BCG vaccine	40
Quantitation and characterization of serotype 6A activation for pneumococcal conjugate vaccine by cryo-EM and SEC methods	40
General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis	39
Impact analysis of rotavirus vaccination in various geographic regions in Western Europe	39
Knowledge, attitudes, and practices of healthcare providers regarding vaccinating children with cancer in Latin America and the Caribbean	39
Knowledge, attitudes, and practices regarding seasonal influenza vaccination during pregnancy in Costa Rica: A mixed-methods study	39
Prevalence of indications for adult hepatitis A vaccination among hepatitis A outbreak-associated cases, Three US States, 2016–2019	39
Differences in school factors associated with adolescent HPV vaccination initiation and completion coverage in three Australian states	38
HPV vaccination acceptance and perceptions related to fertility and population control in the Gambia: An anthropological analysis	38
Dynamics of global emergency vaccine stockpiles: A systems analysis and application to cholera	38
BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study	38
Parental socioeconomic and psychological determinants of the 2009 pandemic influenza A(H1N1) vaccine uptake in children	38
Expected endpoints from future chikungunya vaccine trial sites informed by serological data and modeling	37
Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic	37
100 years of the Bacillus Calmette-Guérin vaccine	37
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysacchar	37
Measles seroprevalence among individuals serologically tested in Ontario, Canada	36
Immunogenicity and safety of routine 13-valent pneumococcal conjugate vaccination outside recommended age range in patients with hematological malignancies and solid tumors	36
Fear, mistrust, and vaccine hesitancy: Narratives of the dengue vaccine controversy in the Philippines	36
IFITM3-deficient mice as a model for testing influenza virus vaccines via the intramuscular route	36
Influenza vaccination in children with pulmonary disease during the COVID-19 pandemic	36
Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP)	36
Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: A prospective population-based study in rural Bangladesh	36
Have vaccine hesitancy models oversimplified a complex problem to our detriment? The Adapted Royal Society of Canada vaccine uptake framework	36
Disproportionality analysis of reported drug adverse events to assess a potential safety signal for pentavalent vaccine in 2019 in El Salvador	35
Influences of sociodemographic characteristics and parental HPV vaccination hesitancy on HPV vaccination coverage in five US states	35
Influenza vaccination uptake among Canadian adults before and during the COVID-19 pandemic: An analysis of the Canadian Longitudinal study on Aging (CLSA)	35
Social inequalities in COVID-19 vaccine acceptance and uptake for children and adolescents in Montreal, Canada	35
The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs	35
Liposomal co-encapsulation of a novel gemini lipopeptide and a CpG-ODN induces a strong Th1 response with the co-activation of a Th2/Th17 profile and high antibody levels	35
Pre-implementation evaluation for an HPV vaccine provider communication intervention among primary care clinics	35
Social and demographic patterns of influenza vaccination coverage in Norway, influenza seasons 2014/15 to 2020/21	35
Exposure to objective/sensationalist information moderates associations between psychological factors and COVID-19 anti-vaccination attitudes: An experimental study	34
Assessing vaccination intentions and perceptions among pregnant women in Italy: A multicenter cross-sectional study in the context of mandatory policies and the COVID-19 pandemic	34
A template tool for the evaluation of vaccines for emerging pathogens to be used for pregnant and breast-feeding women	34
Racial and ethnic differences among Mpox vaccination recipients by vaccination facility type in New York City—August–December 2022	34
Corrigendum to “I want to chat with a person”: a qualitative longitudinal cohort study in England exploring drivers of sub-optimal childhood vaccination uptake” [Vaccine 62 (2025) 127462]	34
COVID-19 and seasonal influenza: The potential 2021–22 “Twindemic”	34
Editorial Board/Aims and Scope	33
Editorial Board/Aims and Scope	33
Editorial Board/Aims and Scope	33
Editorial Board/Aims and Scope	33
Editorial Board	33
A three antigen hepatitis B vaccine induces T cells to Pres1 and Pres2 which correlate with anti HBs antibody titers: An investigation into the immunological mechanisms contributing to high anti-HBs t	33
Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster	32
Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019–2020	32
Editorial Board/Aims and Scope	32
Adaptive immune response to a wild boar-derived recombinant hepatitis e virus capsid protein challenge in pigs	32
The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) S	32
Editorial Board/Aims and Scope	32
Need for a contingency dimension when planning vaccine development in a pandemic environment	32
Evaluation of anti-Pertussis antibody levels in Iranian infants and children: Is it time to include booster acellular Pertussis Vaccines in the immunization schedule?	32
Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus	31
Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine	31
Corrigendum to, “Attitudes and beliefs of healthcare providers toward vaccination in the United States: A cross-sectional online survey” [Vaccine (2024) Dec 2 42(26) 126437]	31
Views on COVID-19 vaccination of young children in Ireland, results from a cross-sectional survey of parents	31
Staff and caregivers' perceptions of digital storytelling to increase influenza vaccine confidence in an urban safety-net healthcare system	31
Strengthening immunization programs through innovative sub-national public-private partnerships in selected provinces in the Democratic Republic of the Congo	31
Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021–February 2022	31
Long-term surveillance of rotavirus vaccination after implementation of a national immunization program in Finland (2008–2018)	31
Nanoparticles displaying fHbp elicit an enhanced antibody response against meningococcal B isolates compared to low valency fHbp antigens	31

How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?	31
Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observat	30
Documenting human papillomavirus vaccine refusal among adolescents in electronic health records: A mixed methods study	30
County-level correlates of completed HPV vaccination in Indiana	30
Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study	30
“EvoVax” – A rationally designed inactivated Salmonella Typhimurium vaccine induces strong and long-lasting immune responses in pigs	30
Strategies to improve interprofessional communication regarding maternal and infant RSV immunization	30
Safe and efficacious inactivated immersion vaccine against KG+ phenotype of emerging bacterial pathogen Lactococcus garvieae for early developmental stage of rainbow trout (Oncorhynchus mykiss) in Ind	30
The efficacy and safety of SYN023 (Zamerovimab and Mazorelvimab injection), the recombinant humanized anti-rabies virus monoclonal antibody mixture, combined with rabies vaccine in a WHO category III	30
‘My primary purpose is to protect the unborn child’: Understanding pregnant women’s perceptions of maternal vaccination and vaccine trials in Europe	29
Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: A phase 3 open-label study	29
Comparison of performance of varicella vaccines via infectious disease modeling	29
Response to letter to the editor: Immunophenotyping of SARS-CoV-2 and vaccine design	29
Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: A prospective observational cohort study	29
COVID-19 vaccine preferences in India	29
Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization R	29
Mathematical modelling of the 100-day target for vaccine availability after the detection of a novel pathogen: A case study in Indonesia	29
Epigenetic changes related to glucose metabolism in type 1 diabetes after BCG vaccinations: A vital role for KDM2B	29
How manufacturing won or lost the COVID-19 vaccine race	29
Impact of electronic immunization registries and electronic logistics management information systems in four low-and middle-income countries: Guinea, Honduras, Rwanda, and Tanzania	29
Evaluation of three hemagglutinin-based vaccines for the experimental control of a panzootic clade 2.3.4.4b A(H5N8) high pathogenicity avian influenza virus in mule ducks	29
Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection	29
Coverage of influenza, pneumococcal and zoster vaccination and determinants of influenza and pneumococcal vaccination among adults with cardiovascular diseases in community	28
Impact of prior infection and repeated vaccination on post-vaccination antibody titers of the influenza A(H1N1)pdm09 strain in Taiwan schoolchildren: Implications for public health	28
Frequency and temporal evolution of COVID-19 vaccination rate among oncological patients undergoing 18F-FDG-PET	28
Evaluation of the humoral response to the third dose of SARS-COV-2 vaccines in liver transplant recipients	28
Donor Unrestricted T Cells: Linking innate and adaptive immunity	28
Associations between family planning, healthcare access, and female education and vaccination among under-immunized children	28
Evaluation of bird-adapted self-amplifying mRNA vaccine formulations in chickens	28
Editorial Board	28
Harmonized case definitions for endpoints in vaccine efficacy trials are needed	28
Corrigendum to “Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III tria	28
Comparing performance of year-round and campaign-mode influenza vaccination strategies among children aged 6–23 months in Kenya: 2019–2021	28
Changes in depressive symptoms and antibody production following influenza vaccination in adolescents and adults	28
The impact of COVID-19 childhood and adolescent vaccination on mortality in Argentina	28
Aggregating human judgment probabilistic predictions of the safety, efficacy, and timing of a COVID-19 vaccine	28
Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection	28
Immune responses and safety of COVID-19 vaccination in atypical hemolytic uremic syndrome patients in Taiwan	28
Immunogenicity and lot-to-lot consistency of booster shot with Sabin inactivated poliomyelitis vaccine in Chinese children aged 18–24 Months: A phase Ⅳ clinical trial	28
Impact of national introduction of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Bangladesh: Case-control and time-trend studies	28
Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARS‐Cov-2 B.1.1.529 (Omicron) variant	27
Vaccine value profile for Salmonella enterica serovar Paratyphi A	27
Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan	27
Vaccines against Neisseria meningitidis serogroup B strains – What does genomics reveal on the Portuguese strain’s coverage	27
Prevalence of poliovirus neutralizing antibodies in Italian population: A systematic review and meta-analysis	27
Use of protective antigen of Bacillus anthracis as a model recombinant antigen to evaluate toll-like receptors 2, 3, 4, 7 and 9 agonists in mice using established functional antibody assays, antigen-s	27
Phenotypic and genetic characterization of a next generation live-attenuated yellow fever vaccine candidate	27
Factors associated with vaccination intention and uptake over time in a sample of older Australians	27
Individual-level factors associated with COVID-19 vaccine acceptance among U.S. patients with cancer	27
The influenza vaccines roadmap – A better future through improved influenza vaccines	27
Construction of a Lactobacillus plantarum-based claudin-3 targeting delivery system for the development of vaccines against Eimeria tenella	27
COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic	27
Mapping the distribution of zero-dose children to assess the performance of vaccine delivery strategies and their relationships with measles incidence in Nigeria	27
Analysis of health claims data on vaccination coverage in older adults in Bavaria, Germany: Influenza, pneumococcus and herpes zoster	27
Impact of the surge of COVID-19 Omicron outbreak on the intention of seasonal influenza vaccination in Hong Kong: A cross-sectional study	27
HPV genotyping in biopsies of HSIL and invasive cervical cancers in women living with HIV: A cohort- and a nested -case control study	27
In ovo administration of retinoic acid enhances cell-mediated immune responses against an inactivated H9N2 avian influenza virus vaccine	26
Concordance of self-reported varicella history and serology among adolescent and adult refugee patients at a primary care clinic in Toronto, Canada	26
Antibody kinetics between birth and three months of life in healthy infants with natural exposure to Group B streptococcus: A UK cohort study	26
Weighing the risks and benefits: Parental perspectives on COVID-19 vaccines for 5- to 11-year-old children	26
“COVID is a huge jigsaw puzzle that I am trying to make sense of myself”: Exploring the perceptions towards the COVID-19 vaccine communication strategy in Australia amongst unvaccinated Australian adu	26
Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates	26
COVID-19 vaccine decision-making among Black women: A qualitative study	26
Crowdfunding narratives and the valuation of vaccines for COVID-19	26
Implementation strategies for the first licensed dengue vaccine: A meeting report	26
Are intelligent people more likely to get vaccinated? The association between COVID-19 vaccine adherence and cognitive profiles	26
Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial	26
Pertussis burden and acellular pertussis vaccine effectiveness in high risk children	26
A novel high throughput plate-based method for 2-PE quantification in novel multidose vaccines (R21 malaria, Covishield and Covovax) and combination vaccines (Hexavalent)	26
Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin strains) simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China	25
High prevalence of human papillomavirus (HPV) in unvaccinated adolescent girls in South Africa, particularly those living with HIV	25
Corrigendum to “Dendritic cell targeting peptide plus Salmonella FliCd flagellin fused outer membrane protein H (OmpH) demonstrated increased efficacy against infections caused by different Pasteurell	25
Risk factors and correlates of protection against XBB SARS-CoV-2 infection among health care workers	25
Association of dual COVID-19 and seasonal influenza vaccination with COVID-19 infection and disease severity	25
Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023	25
A broad and potent IgM antibody against tetra-EV-As induced by EVA71 and CVA16 co-immunization	25
Tanzania’s human papillomavirus (HPV) vaccination program: Community awareness, feasibility, and acceptability of a national HPV vaccination program, 2019	25
New-onset anesthesia/paresthesia following the administration of COVID-19 vaccines in Quebec, Canada	25
Intent to receive flu vaccine and influenza vaccination coverage among health professionals during 2019, 2020 and 2021 campaigns in Côte d’Ivoire	25
Enhancing NA immunogenicity through novel VLP designs.	25
Persistence of immunity in children aged 2 months and 7 months – 5 years old after primary immunization with 13-valent pneumococcal conjugate vaccine	25
National introduction of HPV vaccination in Senegal—Successes, challenges, and lessons learned	25
Occupation, Worker Vulnerability, and COVID-19 Vaccination Uptake: Analysis of the Virus Watch prospective cohort study	25
Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged	25
Utility of edible plant-derived exosome-like nanovesicles as a novel delivery platform for vaccine antigen delivery	25
Rotavirus vaccine-derived cases in Belgium: Evidence for reversion of attenuating mutations and alternative causes of gastroenteritis	25
WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global use	24
Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development	24
Comparison of SARS-CoV-2 antibody responses following the second dose of BNT162b2 and mRNA-1273 vaccines in people living with HIV-1	24
Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021–2022	24
Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions	24
Consultation report – considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries	24
Could live attenuated vaccines better control COVID-19?	24
An intranasal nanoparticle vaccine elicits protective immunity against Mycobacterium tuberculosis	24
Delay between COVID-19 complete vaccination and SARS-CoV-2 infection among healthcare workers	24